- Home
- BUSE vs HCM Comparison
BUSE vs HCM Comparison
Compare BUSE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUSE | HCM |
|---|---|---|
| Founded | 1868 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | BUSE | HCM |
|---|---|---|
| Price | $31.28 | $11.54 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $27.17 | $13.75 |
| AVG Volume (30 Days) | ★ 881.7K | 43.0K |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $719,584,000.00 | N/A |
| Revenue This Year | $23.84 | $20.60 |
| Revenue Next Year | $3.82 | $15.62 |
| P/E Ratio | $60.13 | ★ $5.49 |
| Revenue Growth | ★ 55.66 | N/A |
| 52 Week Low | $21.96 | $9.77 |
| 52 Week High | $31.44 | $18.17 |
Technical Indicators
Market Signals| Indicator | BUSE | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 57.06 |
| Support Level | $23.75 | $10.83 |
| Resistance Level | N/A | $11.80 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 99.15 | 88.89 |
Price Performance
Historical ComparisonAbout BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.